![Despite Headwinds, Biosimilars Market Is Growing in 2024](https://getmga.com/wp-content/uploads/2024/07/iStock-1272520901-1080x675.jpg)
Despite Headwinds, Biosimilars Market Is Growing in 2024
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
“A big responsibility is falling on the IRS to deal with this problem, when, in fact, Congress could be dealing with this problem,” Brill said.”
Former President Trump trotted through Washington last week leaving a trail of policy proposals behind him. Two revenue proposals are worth noting.
Over at the Daily Caller, JD Foster recently took aim at an article I wrote about the impending expiration of major provisions of the Tax Cuts and Jobs Act of 2017 (TCJA) on December 31, 2025.
Tuesday’s Senate Judiciary Committee hearing on drug competition was largely as expected: Committee members voiced support for legislative reforms to address features of the current patent system that result in abuses that excessively limit competition.